SRSF2 and Thrombocytopenia: Our final model now predicts in LR-MDS patients with thrombocytopenia (platelet count ≤50/nl) an HI-P rate of 42% after ROM treatment, in patients additionally harboring an SRSF2 mutation an HI-P rate of 65% and in SRSF2mut patients with baseline hemoglobin levels greater than 11.4 g/dl an HI-P rate of 100% compared to 36% in patients with hemoglobin levels lower than 11.4 g/dl (p = 0.024) (Fig. 3).